Tami Rachmilewitz, M.D. joined VBL Therapeutics in 2018 and brings more than 15 years of experience in clinical development and medical affairs roles in the healthcare industry. Prior to joining VBL Therapeutics, she served as medical director and head of pharmacovigilance for NeuroDerm Ltd., an Israel-based, wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation where she was responsible for all development aspects of clinical phase projects, from design to execution. Earlier in her career, Dr. Rachmilewitz acted as clinical program leader for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), leading a pivotal Phase 3 trial in multiple sclerosis, and as clinical development medical advisor for Novartis (NYSE: NVS) with expertise in immunology. Dr. Rachmilewitz earned a doctor of medicine degree from the Hadassah Medical School at the Hebrew University in Jerusalem, Israel, where she also completed her internship and residency in psychiatry.